Clinical trials of tau-based drugs aimed at gain-of-toxic-tau function (e.g., dysregulation of post-translational modifications and tau aggregation) or loss-of-function (microtubule instability) have been conducted in tauopathy patients. The gene discussed is MAPT; the disease is tauopathy.